535 related articles for article (PubMed ID: 31850687)
1. Loss of skeletal muscle index and survival in patients with metastatic colorectal cancer: Secondary analysis of the phase 3 CAIRO3 trial.
Kurk SA; Peeters PHM; Dorresteijn B; de Jong PA; Jourdan M; Creemers GM; Erdkamp FLG; de Jongh FE; Kint PAM; Poppema BJ; Radema SA; Simkens LHJ; Tanis BC; Tjin-A-Ton MLR; Van Der Velden A; Punt CJA; Koopman M; May AM
Cancer Med; 2020 Feb; 9(3):1033-1043. PubMed ID: 31850687
[TBL] [Abstract][Full Text] [Related]
2. Skeletal muscle mass loss and dose-limiting toxicities in metastatic colorectal cancer patients.
Kurk S; Peeters P; Stellato R; Dorresteijn B; de Jong P; Jourdan M; Creemers GJ; Erdkamp F; de Jongh F; Kint P; Simkens L; Tanis B; Tjin-A-Ton M; Van Der Velden A; Punt C; Koopman M; May A
J Cachexia Sarcopenia Muscle; 2019 Aug; 10(4):803-813. PubMed ID: 31094083
[TBL] [Abstract][Full Text] [Related]
3. Trajectory of body mass and skeletal muscle indices and disease progression in metastatic colorectal cancer patients.
Kurk SA; Stellato RK; Peeters PHM; Dorresteijn B; Jourdan M; Oskam MJ; Punt CJA; Koopman M; May AM
Am J Clin Nutr; 2019 Dec; 110(6):1395-1403. PubMed ID: 31515555
[TBL] [Abstract][Full Text] [Related]
4. Impact of different palliative systemic treatments on skeletal muscle mass in metastatic colorectal cancer patients.
Kurk SA; Peeters PHM; Dorresteijn B; de Jong PA; Jourdan M; Kuijf HJ; Punt CJA; Koopman M; May AM
J Cachexia Sarcopenia Muscle; 2018 Oct; 9(5):909-919. PubMed ID: 30144305
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of skeletal muscle density and sarcopenia in patients with pancreatic cancer undergoing first-line chemotherapy: a retrospective observational study.
Kim IH; Choi MH; Lee IS; Hong TH; Lee MA
BMC Cancer; 2021 Jan; 21(1):77. PubMed ID: 33461517
[TBL] [Abstract][Full Text] [Related]
6. Regorafenib Is Associated With Increased Skeletal Muscle Loss Compared to TAS-102 in Metastatic Colorectal Cancer.
Huemer F; Schlintl V; Hecht S; Hackl H; Melchardt T; Rinnerthaler G; Greil R; Weiss L
Clin Colorectal Cancer; 2019 Jun; 18(2):159-166.e3. PubMed ID: 31060856
[TBL] [Abstract][Full Text] [Related]
7. Association between body composition, survival, and toxicity in advanced esophagogastric cancer patients receiving palliative chemotherapy.
Dijksterhuis WPM; Pruijt MJ; van der Woude SO; Klaassen R; Kurk SA; van Oijen MGH; van Laarhoven HWM
J Cachexia Sarcopenia Muscle; 2019 Feb; 10(1):199-206. PubMed ID: 30666831
[TBL] [Abstract][Full Text] [Related]
8. No influence of sarcopenia on survival of ovarian cancer patients in a prospective validation study.
Ubachs J; Koole SN; Lahaye M; Fabris C; Bruijs L; Schagen van Leeuwen J; Schreuder HWR; Hermans RH; de Hingh IH; van der Velden J; Arts HJ; van Ham M; van Dam P; Vuylsteke P; Bastings J; Kruitwagen RFPM; Lambrechts S; Olde Damink SWM; Rensen SS; Van Gorp T; Sonke GS; van Driel WJ
Gynecol Oncol; 2020 Dec; 159(3):706-711. PubMed ID: 33019981
[TBL] [Abstract][Full Text] [Related]
9. Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy, Independent of Body Mass Index.
Choi Y; Oh DY; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Bang YJ
PLoS One; 2015; 10(10):e0139749. PubMed ID: 26437072
[TBL] [Abstract][Full Text] [Related]
10. Sarcopenia supersedes subjective global assessment as a predictor of survival in colorectal cancer.
Vashi PG; Gorsuch K; Wan L; Hill D; Block C; Gupta D
PLoS One; 2019; 14(6):e0218761. PubMed ID: 31220163
[TBL] [Abstract][Full Text] [Related]
11. Impact of skeletal muscle mass in patients with unresectable gastric cancer who received palliative first-line chemotherapy based on 5-fluorouracil.
Matsunaga T; Saito H; Miyauchi W; Shishido Y; Miyatani K; Morimoto M; Murakami Y; Hanaki T; Kihara K; Yamamoto M; Tokuyasu N; Takano S; Sakamoto T; Hasegawa T; Fujiwara Y
BMC Cancer; 2021 Nov; 21(1):1219. PubMed ID: 34774016
[TBL] [Abstract][Full Text] [Related]
12. The relationship between computed tomography-derived body composition, systemic inflammatory response, and survival in patients undergoing surgery for colorectal cancer.
Dolan RD; Almasaudi AS; Dieu LB; Horgan PG; McSorley ST; McMillan DC
J Cachexia Sarcopenia Muscle; 2019 Feb; 10(1):111-122. PubMed ID: 30460764
[TBL] [Abstract][Full Text] [Related]
13. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Simkens LH; van Tinteren H; May A; ten Tije AJ; Creemers GJ; Loosveld OJ; de Jongh FE; Erdkamp FL; Erjavec Z; van der Torren AM; Tol J; Braun HJ; Nieboer P; van der Hoeven JJ; Haasjes JG; Jansen RL; Wals J; Cats A; Derleyn VA; Honkoop AH; Mol L; Punt CJ; Koopman M
Lancet; 2015 May; 385(9980):1843-52. PubMed ID: 25862517
[TBL] [Abstract][Full Text] [Related]
14. The effect of nutritional counseling on muscle mass and treatment outcome in patients with metastatic colorectal cancer undergoing chemotherapy: A randomized controlled trial.
van der Werf A; Langius JAE; Beeker A; Ten Tije AJ; Vulink AJ; Haringhuizen A; Berkhof J; van der Vliet HJ; Verheul HMW; de van der Schueren MAE
Clin Nutr; 2020 Oct; 39(10):3005-3013. PubMed ID: 32037284
[TBL] [Abstract][Full Text] [Related]
15. Loss of skeletal muscle mass during palliative chemotherapy is a poor prognostic factor in patients with advanced gastric cancer.
Park SE; Choi JH; Park JY; Kim BJ; Kim JG; Kim JW; Park JM; Chi KC; Hwang IG
Sci Rep; 2020 Oct; 10(1):17683. PubMed ID: 33077864
[TBL] [Abstract][Full Text] [Related]
16. Loss of Muscle Mass During Chemotherapy Is Predictive for Poor Survival of Patients With Metastatic Colorectal Cancer.
Blauwhoff-Buskermolen S; Versteeg KS; de van der Schueren MA; den Braver NR; Berkhof J; Langius JA; Verheul HM
J Clin Oncol; 2016 Apr; 34(12):1339-44. PubMed ID: 26903572
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer.
Sherman SK; Lange JJ; Dahdaleh FS; Rajeev R; Gamblin TC; Polite BN; Turaga KK
JAMA Oncol; 2019 Feb; 5(2):236-242. PubMed ID: 30489611
[TBL] [Abstract][Full Text] [Related]
18. Assessment of muscle mass using chest computed tomography-based quantitative and qualitative measurements in patients with systemic sclerosis: A retrospective study with cross-sectional and longitudinal analyses.
da Rocha DS; Tessari JA; Mainardi NB; Hax V; Gasparin AA; de Oliveira CAV; Garcia TS; Xavier RM; Chakr RMDS
Semin Arthritis Rheum; 2023 Apr; 59():152168. PubMed ID: 36736023
[TBL] [Abstract][Full Text] [Related]
19. Skeletal muscle loss during systemic chemotherapy for colorectal cancer indicates treatment response: a pooled analysis of a multicenter clinical trial (KSCC 1605-A).
Sasaki S; Oki E; Saeki H; Shimose T; Sakamoto S; Hu Q; Kudo K; Tsuda Y; Nakashima Y; Ando K; Akagi Y; Kakeji Y; Baba H; Maehara Y
Int J Clin Oncol; 2019 Oct; 24(10):1204-1213. PubMed ID: 31062115
[TBL] [Abstract][Full Text] [Related]
20. Capecitabine plus bevacizumab versus capecitabine in maintenance treatment for untreated characterised KRAS exon 2 wild-type metastatic colorectal cancer: a retrospective analysis in Chinese postmenopausal women.
Su J; Lai J; Yang R; Xu B; Zhu Y; Zhao M; Yang C; Liang G
BMC Gastroenterol; 2019 Jan; 19(1):17. PubMed ID: 30683047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
